内部人交易记录
董事基于 2 个已确定 T+90 收益的买入信号。收益基准:公布次日的收盘价。
Explore the detailed record of transactions filed by Neupert Peter M, 董事. Insider active across 4 companies, notably Adaptive Biotechnologies Corp. Cumulatively, 22 filings have been recorded. Breakdown: 3 buys · 3 sells. Total volume traded: €3.4m. History available since 26 January 2022. The latest transaction was disclosed on 17 August 2026 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Neupert Peter M
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报22 总计
15,000 股@ US$6.320.0025% mcap2.7% 占其流量Common StockSEC:0001237566-26-000003:0
15,000 股@ US$25.230.0098% mcap10.7% 占其流量Common StockSEC:0001237566-26-000003:1
40,000 股@ US$25.100.026% mcap28.3% 占其流量Common StockSEC:0001237566-26-000003:2
69,690 股@ US$25.160.045% mcap49.4% 占其流量Common StockSEC:0001237566-26-000003:3
15,625 股0Common StockSEC:0001237566-26-000001:0
897 股Common StockSEC:0000920148-26-000075:0
30,000 股@ US$6.7940.5% 占其流量Common StockSEC:0001127602-25-020326:0
7,282 股0Common StockSEC:0001127602-25-014729:0
50,000 股@ US$4.0767.7% 占其流量Common StockSEC:0001062993-25-005299:0
15,394 股0Common StockSEC:0001062993-25-004805:0
944 股Common StockSEC:0001127602-25-003708:0
6,354 股0Common StockSEC:0001127602-24-020751:0
15,000 股@ US$0.844.2% 占其流量Common StockSEC:0001062993-24-006350:0
31,328 股0Common StockSEC:0001062993-24-005773:0
947 股Common StockSEC:0001127602-24-003890:0
100,000 股@ US$0.8428.1% 占其流量Common StockSEC:0001062993-23-022626:0
11,000 股@ US$25.296100.0% 占其流量Common StockSEC:0001127602-23-023158:0
14,775 股0Common StockSEC:0001062993-23-006335:0
742 股Common StockSEC:0001127602-23-005109:0
1,300 股@ US$262.85100.0% 占其流量Common StockSEC:0001127602-22-005820:0
771 股Common StockSEC:0001127602-22-003412:0
6,689 股0Common StockSEC:0001209191-22-005495:0
About Neupert Peter M
NEUPERT PETER M is Administrateur and has filed 18 disclosures in total. In the 18 sampled filings, there were only purchases, for a total of EUR 731417, mainly through option exercises, between 2022-01-28 and 2026-03-06, in relation to Laboratory CORP of America Holdings, Fortrea Holdings Inc. and Adaptive Biotechnologies Corp.